ENTERA BIO LTD. Share-based Payment Arrangement, Expense
ENTERA BIO LTD. (ENTX) reported Share-based Payment Arrangement, Expense of $2.75 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-27.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2026-03-27
- ENTERA BIO LTD. share-based payment arrangement, expense for fiscal 2025 was $2.75M, a 7.59% increase from fiscal 2024.
- ENTERA BIO LTD. share-based payment arrangement, expense for fiscal 2024 was $2.56M, a 51.33% increase from fiscal 2023.
- ENTERA BIO LTD. share-based payment arrangement, expense for fiscal 2023 was $1.69M, a 24.83% decline from fiscal 2022.
- ENTERA BIO LTD. share-based payment arrangement, expense for fiscal 2022 was $2.25M, a 20.74% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Expense 12 month |
|---|---|
| 2025-12-31 | $2.75M 10-K · filed 2026-03-27 |
| 2024-12-31 | $2.56M 10-K · filed 2026-03-27 |
| 2023-12-31 | $1.69M 10-K · filed 2025-03-28 |
| 2022-12-31 | $2.25M 10-K · filed 2024-03-08 |
| 2021-12-31 | $1.86M 10-K · filed 2023-03-31 |
| 2020-12-31 | $901.00K 10-K · filed 2022-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Allogene Therapeutics, Inc. (ALLO) | United States | $0.574B | -4.33 |